Stock TBIO TELESIS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Telesis Bio, Inc.

Equities

TBIO

US1920031010

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
0.33 USD -6.83% Intraday chart for Telesis Bio, Inc. +3.64% -17.29%
04-18 Telesis Bio, Inc. Announces Appointment of Eric Esser to the Board of Directors CI
04-18 Telesis Bio Inc. Announces Strategic Focus on Game-Changing Gibson Sola Enzymatic DNA Synthesis Platform and BioXp mRNA Solutions CI

Evolution of the average Target Price on Telesis Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

98eeeb2f56ceafbbff0f04188a.meQG1855-8YFPVJ9DX6dme9jMAeGI_VpT4lI7Wp2kO8.75Ey5aBAsap9VCUUNDvH06xUSjH-bb0sIdwloj8U6N7ajlS9iCqUrVZsEw~2bafef2f828a75d2d80bda5636e88fb8

Analyst Recommendations on Telesis Bio, Inc.

KeyBanc Downgrades Telesis Bio to Sector Weight From Overweight, Cites 'Limited Top-Line Visibility' Amid 'Tepid Biopharma Spending Environment' MT
KeyBanc Capital Markets Adjusts Price Target on Codex DNA to $5 From $8, Maintains Overweight Rating MT
KeyBanc Adjusts Codex DNA's Price Target to $8 From $30, Keeps Overweight Rating MT
CODEX DNA : Cowen Starts Codex DNA at Outperform MT
CODEX DNA : Jefferies Starts Codex DNA at Buy With $23 Price Target MT
CODEX DNA : KeyBanc Starts Codex DNA at Overweight With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.33
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Telesis Bio, Inc.

KeyBanc Capital Markets
Cowen
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TBIO Stock
  4. Consensus Telesis Bio, Inc.